mika wird in Deutschland entwickelt und alle Daten werden anonymisiert und nach höchsten Sicherheitsstandards auf Servern in Deutschland gespeichert. Unser Geschäftsmodell ist ausdrücklich nicht die Weitergabe von Patienteninformationen. Wir möchten Menschen in der Krebstherapie einen Dienst bieten, der ihnen eine echte Hilfe ist.
VivoSense, also known as Vivonoetics are a data analysis and software company specializing in wearable sensor physiological monitoring solutions for research and clinical trials.
Nucleai Ltd. is a company that specializes in AI-powered pathology technology aimed at enhancing cancer detection and treatment. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's platform analyzes tissue samples to provide insights into cancer biology, which aids in biomarker discovery and improves clinical trial outcomes. The company serves hospitals and laboratories in the United States and Israel, collaborating with leading pharmaceutical firms to license its research platform for internal applications and participate in biomarker discovery projects. By leveraging unique tissue datasets, Nucleai seeks to transform the precision oncology landscape, ultimately improving patient care.
VeriSIM Life, Inc. develops disease-specific biosimulation models that allow researchers at pharmaceutical companies to model in software how a drug will interact in animals. The company was incorporated in 2017 and is based in San Francisco, California.
Mekonos Inc. is a technology company based in San Francisco, California, focused on the design, development, and production of gene and cell therapies. Founded in 2017, Mekonos has developed a proprietary cell-engineering platform that utilizes scalable silicon technology and an integrated system-on-a-chip. This platform enables the creation of predictive models for drug discovery and development, as well as a silicon chip automated architecture for genome editing. The company's innovative MEMS technology allows for the precise control of individual nanoneedles to inject single cells in parallel, facilitating the industrialization of engineered therapies for genetic diseases, including cancers. By providing a reliable and reusable manufacturing system, Mekonos aims to enable healthcare providers to deliver a diverse range of therapeutic molecules across various primary cell types.
Carevive Systems, Inc. is a healthcare technology company that specializes in developing a platform to enhance cancer care delivery and patient engagement. Based in North Miami, Florida, the company offers a range of tools including Carevive PROmpt, which facilitates treatment planning, symptom management, and survivorship care through a combination of electronic patient-reported outcomes (ePRO) and evidence-based care plans. Additionally, Carevive provides a Navigation/Care Coordination module that streamlines documentation and tracking of patient care plans, as well as a Risk Stratification model to identify at-risk patients. The platform integrates clinical data with patient-reported outcomes, enabling oncology practices to deliver personalized, dynamic care plans that improve clinical outcomes and support value-based care models. Carevive Systems was established in 2013 and previously operated under the name On Q Health, Inc. until its rebranding in 2015.
Voluntis, Inc. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. It offers Insulia, a prescription-only medical device that provides type 2 diabetes patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Voluntis, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Oncomfort SA specializes in developing innovative digital sedation solutions aimed at alleviating pain and anxiety in patients undergoing medical procedures. Founded in 2017 and based in Wavre, Belgium, the company offers Sedakit, a portable, all-in-one device that delivers digital sedation therapy. This therapy integrates clinical hypnotherapy and various therapeutic techniques through virtual reality, providing a non-pharmacological approach to managing anxiety and discomfort. By utilizing evidence-based methods, Oncomfort's technology enhances patient comfort throughout their medical journey, addressing the psychological and emotional challenges associated with medical treatments.
Nucleai Ltd. is a company that specializes in AI-powered pathology technology aimed at enhancing cancer detection and treatment. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's platform analyzes tissue samples to provide insights into cancer biology, which aids in biomarker discovery and improves clinical trial outcomes. The company serves hospitals and laboratories in the United States and Israel, collaborating with leading pharmaceutical firms to license its research platform for internal applications and participate in biomarker discovery projects. By leveraging unique tissue datasets, Nucleai seeks to transform the precision oncology landscape, ultimately improving patient care.
Nucleai Ltd. is a company that specializes in AI-powered pathology technology aimed at enhancing cancer detection and treatment. Founded in 2017 and headquartered in Tel Aviv-Yafo, Israel, Nucleai's platform analyzes tissue samples to provide insights into cancer biology, which aids in biomarker discovery and improves clinical trial outcomes. The company serves hospitals and laboratories in the United States and Israel, collaborating with leading pharmaceutical firms to license its research platform for internal applications and participate in biomarker discovery projects. By leveraging unique tissue datasets, Nucleai seeks to transform the precision oncology landscape, ultimately improving patient care.
Carevive Systems, Inc. is a healthcare technology company that specializes in developing a platform to enhance cancer care delivery and patient engagement. Based in North Miami, Florida, the company offers a range of tools including Carevive PROmpt, which facilitates treatment planning, symptom management, and survivorship care through a combination of electronic patient-reported outcomes (ePRO) and evidence-based care plans. Additionally, Carevive provides a Navigation/Care Coordination module that streamlines documentation and tracking of patient care plans, as well as a Risk Stratification model to identify at-risk patients. The platform integrates clinical data with patient-reported outcomes, enabling oncology practices to deliver personalized, dynamic care plans that improve clinical outcomes and support value-based care models. Carevive Systems was established in 2013 and previously operated under the name On Q Health, Inc. until its rebranding in 2015.
Novadiscovery SAS, established in 2010 and located in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. This innovative platform assists pharmaceutical and biotechnology companies in conducting virtual trials, allowing them to predict the clinical benefits of new drugs prior to human testing. Jinko focuses on various therapeutic areas, including immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By utilizing advanced mathematics and intelligent algorithms, Novadiscovery creates a community of virtual patients, enabling researchers to optimize drug discovery processes, reduce risks, and minimize costs associated with bringing new drugs to market.
BC Platforms specializes in genomic data management solutions aimed at tackling significant healthcare challenges. The company offers a robust data management platform that facilitates the integration, secure analysis, and interpretation of molecular and clinical data. By combining genomics with IT, BC Platforms empowers health organizations to make informed decisions in drug development and delivery. Their systematic and standardized approach allows for efficient handling of complex health data, ultimately supporting improved outcomes in healthcare.
Little Green House operates a chain of educational centers dedicated to enhancing children's cognitive abilities while prioritizing their emotional well-being and social skills. The organization aims to create an inclusive environment where children can express themselves freely and pursue their individual growth. Its centers offer diverse developmental activities, including play areas, site visits, and opportunities for learning musical instruments, all designed to foster the holistic development of children. Through these initiatives, Little Green House seeks to support the overall growth and development of young learners in a nurturing atmosphere.
Kaiku Health Oy develops and delivers user-centered software solutions for patients, doctors, and nurses to communicate online. It develops a communication and follow-up solution for cancer patients to communicate with medical staff in Swedish, English, German, and Finnish languages. The company serves clinics and university hospitals in Finland, Sweden, and Switzerland. Kaiku Health Oy was formerly known as Netmedi Oy and changed its name to Kaiku Health Oy in September 2017. The company was founded in 2012 and is based in Helsinki, Finland. As of May 15, 2020, Kaiku Health Oy operates as a subsidiary of Elekta AB (publ).
ABAC Therapeutics S.A. develops precision antimicrobial agents for precision treatment of MDR Gram-negative infections. It offers PasNas, a drug discovery platform unveiling pathogen-specific antibacterial properties of molecules while promoting the compounds active against MDR strains with new mechanism of action and with maximized chances of success in clinical development. The company was incorporated in 2014 and is based in Barcelona, Spain. As of November 20, 2019, ABAC Therapeutics S.A. operates as a subsidiary of Tibidabo Ventures.
BC Platforms specializes in genomic data management solutions aimed at tackling significant healthcare challenges. The company offers a robust data management platform that facilitates the integration, secure analysis, and interpretation of molecular and clinical data. By combining genomics with IT, BC Platforms empowers health organizations to make informed decisions in drug development and delivery. Their systematic and standardized approach allows for efficient handling of complex health data, ultimately supporting improved outcomes in healthcare.
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.
BPA Solutions SA specializes in providing innovative business applications that enhance Microsoft SharePoint and Office 365. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a range of solutions including BPA CRM for customer relationship management, BPA Quality for quality management, and BPA Risk for tracking business activities in complex environments. Additional offerings include BPA Project for project management, BPA Recruiting for candidate management, and Self-Service tools for process sharing. BPA Solutions also features a Solutions Suite to monitor critical business processes and mobile solutions, along with professional services such as training, consulting, and support. The company delivers its software on-premise, through private or Microsoft clouds, and in hybrid environments, serving clients globally.
Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.
KeyLemon S.A., founded in 2008 by Gilles Florey and Yann Rodriguez in Martigny, Switzerland, specializes in biometric authentication technology, particularly through face recognition. The company aims to provide a seamless and secure user experience by allowing devices to recognize their owners naturally, eliminating the need for passwords. KeyLemon has developed innovative solutions, including its flagship product, Oasis, which enables mobile authentication by simply taking a selfie. This technology is designed for various applications, enhancing secure access to high-value services such as banking and payment across multiple devices and systems. Over the years, KeyLemon has established itself as a leader in biometric solutions, serving a diverse clientele globally while remaining committed to continuous improvement in user recognition and security. As of 2018, KeyLemon operates as a subsidiary of ams AG.
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.
Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...
Compliant Concept is a spinoff of the Empa and the ETH Zurich. They develop intelligent bed systems for the treatment and prevention of pressure ulcers.
compliant concept is a spin-off of ETH Zurich and Empa, with its roots in Empa's Laboratory for Mechanics for Modeling and Simulation.
Their goal is to make the care of hospital patients and nursing home residents safer, more efficient and more comfortable.
Spinomix is a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector. Based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is building the new gold standard for the processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety. Spinomix’ products MagPhase™ and FibroTrap™ improve the accuracy and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse (e.g. blood, urine, swabs and food matrices). Today many aspects of sample processing are still labour and time intensive. Therefore, there is a significant opportunity for Spinomix’s technologies to streamline the process. They are targeting double-digit growth markets such as nucleic acids extraction, believed to be worth $2 billion; cell separation growing to over $2.5 billion; food safety at over $2 billion; and molecular diagnostics for infectious diseases estimated at $2.7 billion. Their current approach is to concentrate on product innovation and market validation. They have collaboration agreements in place and are conducting validation programs of their products with key market players in research and industry. Their goal is to develop these collaborations into strategic commercial partnerships to license their products.
Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.
Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.
Tweasy helps businesses stay close to their customers and grow strong and profitable relationships. The Tweasy application brings together all the news, promotions, surveys and information generated by businesses, clubs and associations to help them communicate.
Immunexpress Pty Ltd is a molecular diagnostics company based in Brisbane, Australia, with an additional office in Seattle, Washington. Founded in 2006, the company specializes in developing clinical assays aimed at the early detection and management of sepsis, particularly in patients at risk. Immunexpress focuses on the discovery and clinical validation of genomic and proteomic biomarkers, translating these findings into diagnostic and monitoring assays suitable for point-of-care applications. Its key products include SeptiCyte Triage, designed for screening sepsis in emergency and intensive care units; SeptiCyte STAT, which monitors high-risk patients in ICUs and post-operative wards; and SeptiCyte RTT, a tool for assessing the immune status of ICU patients with sepsis. The approach taken by Immunexpress utilizes blood gene expression to quantify the immune response to pathogens, moving away from traditional methods that seek to identify the causative pathogen.
Private Equity Round in 2012
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.
Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.
Curis, Inc. is a biotechnology company focused on the discovery and development of innovative drug candidates for the treatment of various human cancers. Based in Lexington, Massachusetts, Curis is advancing several clinical-stage drug candidates, including CA-4948, an oral small molecule currently in Phase I trials for non-Hodgkin lymphomas and acute myeloid leukemia, and Fimepinostat, which targets specific enzymes for MYC-altered diffuse large B-cell lymphoma. The company also has additional pipeline products such as CA-170 for advanced solid tumors and CA-327, which is in the pre-investigational new drug stage. Curis collaborates with notable partners like F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development of Erivedge, a small molecule designed to inhibit the hedgehog signaling pathway in advanced basal cell carcinoma, among other partnerships aimed at enhancing immuno-oncology and precision oncology efforts. Founded in 2000, Curis aims to leverage its expertise in signaling pathways to create targeted cancer therapies.
Neovacs S.A. is a biotechnology company based in Paris, France, that specializes in the development of therapeutic vaccines known as "Kinoids" for treating autoimmune, inflammatory diseases, allergies, and cancer. Founded in 1993 by Professor Daniel Zagury, the company aims to create innovative treatments that stimulate a natural polyclonal antibody response in patients, contrasting with traditional monoclonal antibody therapies. Neovacs' product pipeline includes IFNa Kinoid, which is undergoing Phase IIb clinical trials for systemic lupus erythematosus and Phase IIa trials for dermatomyositis, along with preclinical developments targeting diabetes. Additionally, the company is working on VEGF-Kinoid for age-related macular degeneration and solid tumors, and IL-4/IL-13 Kinoid for allergies. Neovacs also collaborates with the Sunnybrook Research Institute to advance preclinical research on VEGF-Kinoid for colorectal and ovarian cancer. The company holds a broad patent portfolio and is recognized as a pioneer in the field of therapeutic vaccines.